RedHill Biopharma Ltd. (NASDAQ:RDHL) Sees Significant Increase in Short Interest

RedHill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 417,400 shares, a growth of 23.1% from the July 15th total of 339,200 shares. Approximately 1.3% of the shares of the stock are sold short. Based on an average daily volume of 6,580,000 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on RedHill Biopharma in a research report on Friday. They issued a “hold” rating for the company.

Institutional Investors Weigh In On RedHill Biopharma

A hedge fund recently raised its stake in RedHill Biopharma stock. Gagnon Securities LLC grew its stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) by 32.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 118,360 shares of the biotechnology company’s stock after acquiring an additional 28,771 shares during the period. Gagnon Securities LLC owned about 0.40% of RedHill Biopharma worth $63,000 at the end of the most recent reporting period. 7.20% of the stock is owned by hedge funds and other institutional investors.

RedHill Biopharma Stock Performance

RDHL traded down $0.08 during trading on Friday, reaching $0.29. The stock had a trading volume of 2,379,580 shares, compared to its average volume of 3,311,910. RedHill Biopharma has a 1-year low of $0.26 and a 1-year high of $3.28. The stock has a 50 day moving average of $0.40 and a two-hundred day moving average of $0.46.

Shares of RedHill Biopharma are set to reverse split before the market opens on Tuesday, August 20th. The 1-25 reverse split was announced on Friday, August 16th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, August 19th.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.